Symbols / ALEC Stock $2.45 -0.41% Alector, Inc.
ALEC (Stock) Chart
About
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 270.39M | Enterprise Value | 50.60M | Income | -142.93M | Sales | 21.05M | Book/sh | 0.28 | Cash/sh | 2.32 |
| Dividend Yield | — | Payout | 0.00% | Employees | 103 | IPO | — | P/E | — | Forward P/E | -2.78 |
| PEG | — | P/S | 12.85 | P/B | 8.81 | P/C | — | EV/EBITDA | -0.34 | EV/Sales | 2.40 |
| Quick Ratio | 3.68 | Current Ratio | 3.83 | Debt/Eq | 118.22 | LT Debt/Eq | — | EPS (ttm) | -1.39 | EPS next Y | -0.88 |
| EPS Growth | — | Revenue Growth | -88.50% | Earnings | 2026-05-11 | ROA | -25.13% | ROE | -181.56% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -5.88% | Profit Margin | 0.00% | Shs Outstand | 110.36M | Shs Float | 86.30M | Short Float | 7.03% |
| Short Ratio | 8.17 | Short Interest | — | 52W High | 3.40 | 52W Low | 0.97 | Beta | 0.58 | Avg Volume | 795.76K |
| Volume | 1.42M | Target Price | $2.88 | Recom | Hold | Prev Close | $2.46 | Price | $2.45 | Change | -0.41% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-15 | up | Cantor Fitzgerald | Neutral → Overweight | — |
| 2026-03-10 | up | BTIG | Neutral → Buy | $6 |
| 2025-10-22 | down | TD Cowen | Buy → Hold | — |
| 2025-10-22 | down | Cantor Fitzgerald | Overweight → Neutral | — |
| 2025-10-22 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-10-22 | down | William Blair | Outperform → Market Perform | — |
| 2025-10-22 | down | BTIG | Buy → Neutral | — |
| 2025-09-25 | reit | BTIG | Buy → Buy | $5 |
| 2025-07-28 | up | Mizuho | Neutral → Outperform | $4 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-02-27 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-12-16 | down | Stifel | Buy → Hold | $4 |
| 2024-11-26 | down | Morgan Stanley | Equal-Weight → Underweight | $3 |
| 2024-11-26 | main | BTIG | Buy → Buy | $5 |
| 2024-11-26 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-11-07 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2024-09-17 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-09-09 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-07-29 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-06-20 | reit | Cantor Fitzgerald | — → Overweight | — |
- Alector (ALEC) Stock: Future Performance Expectations (Buying Pressure) 2026-04-20 - Elite Alerts - UBND thành phố Hải Phòng ue, 21 Apr 2026 04
- Alector (ALEC) accounting officer sells 1,820 shares in 10b5-1 trade - Stock Titan Fri, 17 Apr 2026 21
- Alector stock upgraded at Cantor Fitzgerald (ALEC:NASDAQ) - Seeking Alpha Wed, 15 Apr 2026 15
- INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint - PR Newswire hu, 29 Jan 2026 08
- $ALEC stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Wed, 01 Apr 2026 07
- How The Narrative Around Alector (ALEC) Is Shifting After Index Removal And New Targets - Yahoo Finance ue, 03 Feb 2026 08
- ALEC Stock Price and Chart — DFM:ALEC - TradingView hu, 18 Sep 2025 13
- Alector stock plummets after Phase 3 trial failure in FTD treatment - Investing.com ue, 21 Oct 2025 07
- Is Alector (ALEC) Stock a Buy Now | Price at $2.46, Down 0.20% - Stock Trading Network - Cổng thông tin điện tử Tỉnh Sơn La Wed, 08 Apr 2026 07
- ALEC (NASDAQ: ALEC) affiliate reports multiple common-stock sales in Mar 2026 - Stock Titan hu, 16 Apr 2026 20
- $ALEC stock is down 51% today. Here's what we see in our data. - Quiver Quantitative Wed, 22 Oct 2025 07
- Alector stock upgraded at BTIG (ALEC:NASDAQ) - Seeking Alpha ue, 10 Mar 2026 07
- Alector (ALEC) Stock: Why It Matters Now (Trades Higher) 2026-04-20 - Bearish Pattern - Cổng thông tin điện tử tỉnh Lào Cai Mon, 20 Apr 2026 15
- Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst (ALEC) - Seeking Alpha ue, 16 Dec 2025 08
- Vanguard disaggregates holdings; reports 0% in Alector (ALEC) - Stock Titan hu, 26 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
21.05
-79.07%
|
100.56
+3.60%
|
97.06
-27.36%
|
133.62
|
| Operating Revenue |
|
21.05
-79.07%
|
100.56
+3.60%
|
97.06
-27.36%
|
133.62
|
| Operating Expense |
|
177.05
-27.90%
|
245.56
-1.31%
|
248.80
-8.34%
|
271.45
|
| Research And Development |
|
123.06
-33.81%
|
185.94
-3.21%
|
192.12
-8.70%
|
210.42
|
| Selling General And Administration |
|
53.99
-9.44%
|
59.62
+5.17%
|
56.69
-7.12%
|
61.03
|
| General And Administrative Expense |
|
53.99
-9.44%
|
59.62
+5.17%
|
56.69
-7.12%
|
61.03
|
| Other Gand A |
|
53.99
-9.44%
|
59.62
+5.17%
|
56.69
-7.12%
|
61.03
|
| Total Expenses |
|
177.05
-27.90%
|
245.56
-1.31%
|
248.80
-8.34%
|
271.45
|
| Operating Income |
|
-156.01
-7.59%
|
-145.00
+4.44%
|
-151.74
-10.09%
|
-137.83
|
| Total Operating Income As Reported |
|
-156.01
-7.59%
|
-145.00
+4.44%
|
-151.74
-10.09%
|
-137.83
|
| EBITDA |
|
-146.35
-7.48%
|
-136.16
+4.71%
|
-142.89
-10.46%
|
-129.36
|
| Normalized EBITDA |
|
-146.35
-7.48%
|
-136.16
+4.71%
|
-142.89
-10.46%
|
-129.36
|
| Reconciled Depreciation |
|
9.66
+9.27%
|
8.84
-0.08%
|
8.85
+4.44%
|
8.47
|
| EBIT |
|
-156.01
-7.59%
|
-145.00
+4.44%
|
-151.74
-10.09%
|
-137.83
|
| Net Income |
|
-142.93
-20.06%
|
-119.05
+8.70%
|
-130.39
+2.19%
|
-133.31
|
| Pretax Income |
|
-142.76
-20.05%
|
-118.92
+5.00%
|
-125.18
+3.75%
|
-130.06
|
| Other Income Expense |
|
13.25
-49.20%
|
26.08
-1.83%
|
26.56
+241.49%
|
7.78
|
| Other Non Operating Income Expenses |
|
13.25
-49.20%
|
26.08
-1.83%
|
26.56
+241.49%
|
7.78
|
| Tax Provision |
|
0.17
+31.25%
|
0.13
-97.54%
|
5.21
+60.17%
|
3.25
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-142.93
-20.06%
|
-119.05
+8.70%
|
-130.39
+2.19%
|
-133.31
|
| Net Income From Continuing Operation Net Minority Interest |
|
-142.93
-20.06%
|
-119.05
+8.70%
|
-130.39
+2.19%
|
-133.31
|
| Net Income From Continuing And Discontinued Operation |
|
-142.93
-20.06%
|
-119.05
+8.70%
|
-130.39
+2.19%
|
-133.31
|
| Net Income Continuous Operations |
|
-142.93
-20.06%
|
-119.05
+8.70%
|
-130.39
+2.19%
|
-133.31
|
| Normalized Income |
|
-142.93
-20.06%
|
-119.05
+8.70%
|
-130.39
+2.19%
|
-133.31
|
| Net Income Common Stockholders |
|
-142.93
-20.06%
|
-119.05
+8.70%
|
-130.39
+2.19%
|
-133.31
|
| Diluted EPS |
|
-1.39
-13.01%
|
-1.23
+21.15%
|
-1.56
+3.70%
|
-1.62
|
| Basic EPS |
|
-1.39
-13.01%
|
-1.23
+21.15%
|
-1.56
+3.70%
|
-1.62
|
| Basic Average Shares |
|
103.00
+6.64%
|
96.59
+15.35%
|
83.73
+1.54%
|
82.47
|
| Diluted Average Shares |
|
103.00
+6.64%
|
96.59
+15.35%
|
83.73
+1.54%
|
82.47
|
| Diluted NI Availto Com Stockholders |
|
-142.93
-20.06%
|
-119.05
+8.70%
|
-130.39
+2.19%
|
-133.31
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
293.24
-37.38%
|
468.30
-24.69%
|
621.83
-21.05%
|
787.65
|
| Current Assets |
|
266.45
-37.28%
|
424.82
-24.92%
|
565.81
-22.11%
|
726.43
|
| Cash Cash Equivalents And Short Term Investments |
|
256.02
-38.07%
|
413.40
-24.68%
|
548.86
-23.00%
|
712.85
|
| Cash And Cash Equivalents |
|
65.80
+99.27%
|
33.02
-55.71%
|
74.56
-51.69%
|
154.32
|
| Other Short Term Investments |
|
190.22
-49.99%
|
380.38
-19.80%
|
474.31
-15.08%
|
558.53
|
| Receivables |
|
—
|
—
|
0.00
-100.00%
|
2.59
|
| Prepaid Assets |
|
—
|
—
|
—
|
11.00
|
| Other Current Assets |
|
10.43
-8.69%
|
11.42
-32.61%
|
16.95
+54.10%
|
11.00
|
| Total Non Current Assets |
|
26.79
-38.41%
|
43.49
-22.37%
|
56.02
-8.48%
|
61.21
|
| Net PPE |
|
24.55
-33.81%
|
37.10
-21.17%
|
47.06
-11.77%
|
53.33
|
| Gross PPE |
|
62.05
-11.41%
|
70.04
-6.75%
|
75.11
-1.10%
|
75.94
|
| Accumulated Depreciation |
|
-37.49
-13.82%
|
-32.94
-17.44%
|
-28.05
-24.05%
|
-22.61
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
4.85
+0.00%
|
4.85
+0.92%
|
4.80
+1.31%
|
4.74
|
| Other Properties |
|
32.26
-16.94%
|
38.84
-11.11%
|
43.69
-2.86%
|
44.98
|
| Leases |
|
24.94
-5.37%
|
26.36
-0.97%
|
26.62
+1.48%
|
26.23
|
| Other Non Current Assets |
|
2.23
-65.07%
|
6.39
-28.71%
|
8.96
+13.74%
|
7.88
|
| Total Liabilities Net Minority Interest |
|
262.59
-23.11%
|
341.50
-29.97%
|
487.67
-14.92%
|
573.21
|
| Current Liabilities |
|
69.50
-44.42%
|
125.06
-29.72%
|
177.95
+89.69%
|
93.81
|
| Payables And Accrued Expenses |
|
29.01
+12.45%
|
25.80
-18.82%
|
31.77
+28.32%
|
24.76
|
| Payables |
|
18.98
+133.49%
|
8.13
-29.18%
|
11.48
+174.00%
|
4.19
|
| Accounts Payable |
|
1.69
-23.66%
|
2.21
-41.32%
|
3.77
-9.88%
|
4.19
|
| Other Payable |
|
17.29
+192.34%
|
5.91
-23.22%
|
7.70
|
—
|
| Current Accrued Expenses |
|
10.03
-43.24%
|
17.67
-12.96%
|
20.30
-1.34%
|
20.57
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
12.94
-28.95%
|
18.21
+19.06%
|
15.30
+19.90%
|
12.76
|
| Current Debt And Capital Lease Obligation |
|
9.42
+7.63%
|
8.75
+3.45%
|
8.46
+5.00%
|
8.06
|
| Current Debt |
|
0.37
|
—
|
—
|
—
|
| Other Current Borrowings |
|
0.37
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
9.06
+3.45%
|
8.75
+3.45%
|
8.46
+5.00%
|
8.06
|
| Current Deferred Liabilities |
|
6.68
-71.75%
|
23.66
-71.48%
|
82.97
+72.04%
|
48.23
|
| Current Deferred Revenue |
|
6.68
-71.75%
|
23.66
-71.48%
|
82.97
+72.04%
|
48.23
|
| Total Non Current Liabilities Net Minority Interest |
|
193.09
-10.79%
|
216.44
-30.12%
|
309.72
-35.39%
|
479.40
|
| Long Term Debt And Capital Lease Obligation |
|
26.81
-20.60%
|
33.77
+10.86%
|
30.46
-13.64%
|
35.27
|
| Long Term Debt |
|
9.32
-0.70%
|
9.39
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
17.49
-28.26%
|
24.38
-19.96%
|
30.46
-13.64%
|
35.27
|
| Long Term Provisions |
|
—
|
9.28
-86.16%
|
67.05
|
—
|
| Non Current Deferred Liabilities |
|
164.54
-4.43%
|
172.17
-18.34%
|
210.84
-52.44%
|
443.37
|
| Non Current Deferred Revenue |
|
164.54
-4.43%
|
172.17
-18.34%
|
210.84
-52.44%
|
443.37
|
| Other Non Current Liabilities |
|
1.74
+40.76%
|
1.23
-10.12%
|
1.37
+80.90%
|
0.76
|
| Stockholders Equity |
|
30.65
-75.83%
|
126.80
-5.48%
|
134.16
-37.44%
|
214.44
|
| Common Stock Equity |
|
30.65
-75.83%
|
126.80
-5.48%
|
134.16
-37.44%
|
214.44
|
| Capital Stock |
|
0.01
+22.22%
|
0.01
+12.50%
|
0.01
+0.00%
|
0.01
|
| Common Stock |
|
0.01
+22.22%
|
0.01
+12.50%
|
0.01
+0.00%
|
0.01
|
| Share Issued |
|
110.36
+11.38%
|
99.09
+16.74%
|
84.88
+2.39%
|
82.90
|
| Ordinary Shares Number |
|
110.36
+11.38%
|
99.09
+16.74%
|
84.88
+2.39%
|
82.90
|
| Additional Paid In Capital |
|
1,002.53
+4.90%
|
955.66
+13.22%
|
844.04
+5.68%
|
798.70
|
| Retained Earnings |
|
-972.06
-17.24%
|
-829.13
-16.77%
|
-710.08
-22.49%
|
-579.69
|
| Gains Losses Not Affecting Retained Earnings |
|
0.17
-36.40%
|
0.26
+41.85%
|
0.18
+104.02%
|
-4.58
|
| Other Equity Adjustments |
|
0.17
-36.40%
|
0.26
+41.85%
|
0.18
+104.02%
|
-4.58
|
| Total Equity Gross Minority Interest |
|
30.65
-75.83%
|
126.80
-5.48%
|
134.16
-37.44%
|
214.44
|
| Total Capitalization |
|
39.97
-70.65%
|
136.19
+1.51%
|
134.16
-37.44%
|
214.44
|
| Working Capital |
|
196.95
-34.30%
|
299.76
-22.71%
|
387.86
-38.69%
|
632.63
|
| Invested Capital |
|
40.34
-70.38%
|
136.19
+1.51%
|
134.16
-37.44%
|
214.44
|
| Total Debt |
|
36.23
-14.78%
|
42.52
+9.25%
|
38.92
-10.18%
|
43.33
|
| Capital Lease Obligations |
|
26.54
-19.88%
|
33.13
-14.87%
|
38.92
-10.18%
|
43.33
|
| Net Tangible Assets |
|
30.65
-75.83%
|
126.80
-5.48%
|
134.16
-37.44%
|
214.44
|
| Tangible Book Value |
|
30.65
-75.83%
|
126.80
-5.48%
|
134.16
-37.44%
|
214.44
|
| Current Provisions |
|
11.45
-76.46%
|
48.63
+23.31%
|
39.44
|
—
|
| Duefrom Related Parties Current |
|
—
|
—
|
0.00
-100.00%
|
2.59
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-184.03
+19.95%
|
-229.91
-24.84%
|
-184.16
-805.91%
|
-20.33
|
| Cash Flow From Continuing Operating Activities |
|
-184.03
+19.95%
|
-229.91
-24.84%
|
-184.16
-805.91%
|
-20.33
|
| Net Income From Continuing Operations |
|
-142.93
-20.06%
|
-119.05
+8.70%
|
-130.39
+2.19%
|
-133.31
|
| Depreciation Amortization Depletion |
|
9.66
+9.27%
|
8.84
-0.08%
|
8.85
+4.44%
|
8.47
|
| Depreciation |
|
9.66
+9.27%
|
8.84
-0.08%
|
8.85
+4.44%
|
8.47
|
| Depreciation And Amortization |
|
9.66
+9.27%
|
8.84
-0.08%
|
8.85
+4.44%
|
8.47
|
| Other Non Cash Items |
|
0.29
|
—
|
—
|
—
|
| Stock Based Compensation |
|
26.66
-32.45%
|
39.46
-7.79%
|
42.80
-7.26%
|
46.15
|
| Asset Impairment Charge |
|
2.92
+32.52%
|
2.21
|
0.00
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
0.05
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.05
|
0.00
|
| Change In Working Capital |
|
-74.06
+49.62%
|
-146.99
-63.05%
|
-90.15
-251.44%
|
59.53
|
| Change In Receivables |
|
—
|
0.00
-100.00%
|
2.59
-46.15%
|
4.80
|
| Change In Prepaid Assets |
|
0.99
-82.05%
|
5.53
+192.89%
|
-5.95
-51.53%
|
-3.93
|
| Change In Payables And Accrued Expense |
|
-2.05
+28.96%
|
-2.89
-129.27%
|
9.87
+405.92%
|
-3.23
|
| Change In Accrued Expense |
|
-12.90
-3895.29%
|
0.34
-86.65%
|
2.55
+195.89%
|
-2.65
|
| Change In Payable |
|
10.85
+435.94%
|
-3.23
-144.09%
|
7.33
+1380.77%
|
-0.57
|
| Change In Account Payable |
|
-0.52
+63.64%
|
-1.44
-282.23%
|
-0.38
+34.09%
|
-0.57
|
| Change In Other Working Capital |
|
-21.05
+79.07%
|
-100.56
-50.58%
|
-66.78
-200.60%
|
66.38
|
| Change In Other Current Assets |
|
4.16
+44.68%
|
2.87
+384.84%
|
-1.01
-20.84%
|
-0.83
|
| Change In Other Current Liabilities |
|
-56.11
-8.03%
|
-51.94
-79.93%
|
-28.87
-685.90%
|
-3.67
|
| Investing Cash Flow |
|
196.60
+83.51%
|
107.13
+5.11%
|
101.92
+164.09%
|
-159.01
|
| Cash Flow From Continuing Investing Activities |
|
196.60
+83.51%
|
107.13
+5.11%
|
101.92
+164.09%
|
-159.01
|
| Net PPE Purchase And Sale |
|
-0.04
+96.73%
|
-1.25
+47.29%
|
-2.38
+42.17%
|
-4.12
|
| Purchase Of PPE |
|
-0.04
+96.73%
|
-1.25
+47.29%
|
-2.38
+42.17%
|
-4.12
|
| Capital Expenditure |
|
-0.04
+96.73%
|
-1.25
+47.29%
|
-2.38
+42.17%
|
-4.12
|
| Net Investment Purchase And Sale |
|
196.64
+81.42%
|
108.39
+3.92%
|
104.30
+167.33%
|
-154.90
|
| Purchase Of Investment |
|
-271.88
+41.87%
|
-467.74
+15.22%
|
-551.73
+0.93%
|
-556.90
|
| Sale Of Investment |
|
468.52
-18.68%
|
576.13
-12.18%
|
656.03
+63.19%
|
402.00
|
| Financing Cash Flow |
|
20.21
-75.21%
|
81.54
+3097.65%
|
2.55
-43.51%
|
4.51
|
| Cash Flow From Continuing Financing Activities |
|
20.21
-75.21%
|
81.54
+3097.65%
|
2.55
-43.51%
|
4.51
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
9.39
|
0.00
|
0.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
9.39
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
9.39
|
0.00
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
9.39
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
19.98
-71.90%
|
71.11
|
0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.23
-77.76%
|
1.04
-59.10%
|
2.55
-43.51%
|
4.51
|
| Changes In Cash |
|
32.78
+179.50%
|
-41.23
+48.26%
|
-79.69
+54.42%
|
-174.83
|
| Beginning Cash Position |
|
34.87
-54.18%
|
76.10
-51.15%
|
155.79
-52.88%
|
330.62
|
| End Cash Position |
|
67.65
+94.02%
|
34.87
-54.18%
|
76.10
-51.15%
|
155.79
|
| Free Cash Flow |
|
-184.07
+20.37%
|
-231.16
-23.92%
|
-186.54
-663.08%
|
-24.45
|
| Interest Paid Supplemental Data |
|
0.85
|
0.00
|
—
|
—
|
| Amortization Of Securities |
|
-6.58
+54.25%
|
-14.38
+6.13%
|
-15.32
-1217.11%
|
-1.16
|
| Common Stock Issuance |
|
19.98
-71.90%
|
71.11
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
19.98
-71.90%
|
71.11
|
0.00
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-17 View
- 42026-03-13 View
- 42026-03-13 View
- 42026-03-12 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-02-26 View
- 10-K2026-02-25 View
- 8-K2026-02-25 View
- 8-K2025-12-12 View
- 42025-12-08 View
- 42025-12-03 View
- 42025-12-03 View
- 42025-12-03 View
- 42025-12-03 View
- 42025-11-12 View
- 42025-11-12 View
- 42025-11-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|